Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Parabilis Medicines, a clinical-stage biopharmaceutical company developing novel medicines targeting historically undruggable proteins, closed its upsized initial public offering on Nasdaq under ticker PBLS at $20 per share. The IPO raised gross proceeds of $770.5 million, including full exercise of underwriters' over-allotment option. Additionally…